Search
EMA Guideline on Stability Testing for Applications for Variations to a Marketing Authorisation
Post-authorisation changes are an inevitable part of medicinal product lifecycle management, and stability data play a critical role in demonstrating that such changes do not compromise product quality, safety, or efficacy. To harmonise expectations across the EU, the European Medicines Agency has issued Revision 3 of the Guideline on stability testing for applications for variations to a marketing authorisation . Adopted in December 2025 and effective from January 2026, this
Sharan Murugan
Dec 13, 20252 min read
UK MHRA: Guidance on Established Medicines Marketing Authorisation Application Process Changes
The UK Medicines and Healthcare products Regulatory Agency (MHRA) updated its guidance "Established Medicines Marketing Authorisation...
Sharan Murugan
Mar 13, 20241 min read